AXIA INVESTMENTS EMERGES VICTORIOUS AT GLOBAL BRAND AWARDS 2024
AXIA Investments emerges victorious as the "Most Innovative CFD Broker, GCC- 2024" at the distinguished Global Brand Awards.

Commenting on winning the award,
Commenting on winning the award,
ABOUT AXIA INVESTMENTS
Based in
ABOUT GLOBAL BRANDS MAGAZINE (
Global Brands Magazine (GBM) has been at the forefront, bringing news, views and opinions on brands shaping the future of their industry. The
ABOUT THE GLOBAL BRAND AWARDS
Global Brand Awards honours brands for their excellence in performance and rewards companies across different sectors for the quality of their services. The Brand Awards highlight the accomplishments of organisations that have performed remarkably well in finance, education, hospitality, automotive, lifestyle, education, real estate, technology, and others. Global Brand Awards recognise vital players who progress towards excellence by providing a platform to acknowledge their efforts. In addition, GBM strives to create awareness concerning the significance of such organisations and rewards them for their notable efforts with the ultimate global recognition. To learn more about the awards, please visit the Brand Awards Winners section on the GBM website.
To nominate your company or business leader for the Global Brand Awards 2024, please click on the following link:
https://www.globalbrandsmagazine.com/nomination-form/
Check out our social media shout outs through the links below:
Facebook: https://bit.ly/4bWDEIf
Linkedin: https://bit.ly/3yBsbPO
Twitter: https://bit.ly/3V0T1Z4
Instagram: https://bit.ly/3wQJlIG
Logo - https://mma.prnewswire.com/media/2377199/GBM_2024_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/axia-investments-emerges-victorious-at-global-brand-awards-2024-302156167.html
SOURCE Global Brands Magazine
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2026 CSCCP-ASCCP Colposcopy Training Course--Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions
- Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026
- Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share